1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Biden Leaves US FDA Largely Out Of Budget Outline

 
• By Derrick Gingery

FDA is only mentioned once in the document, and its temporary leadership may not be the reason why.

Discarded federal budget documents.
Like these from past years, many likely will discard President Biden's budget proposal. • Source: Alamy

Stakeholders hoping for hints about President Biden’s plans for the US Food and Drug Administration in his fiscal year 2022 budget outline were left wanting, but the lack of any real information is not surprising or necessarily conclusion-generating.

Biden’s FY 2022 so-called “skinny” budget request, a 58-page summary of top-line figures and themes in his spending wish list, only mentioned the FDA one time

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 
• By Derrick Gingery, Sue Sutter, and Nielsen Hobbs

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.

US FDA Layoffs Hit Conflict-Of-Interest Screening For ODAC Meeting

 
• By Sue Sutter and Derrick Gingery

Screening for conflicts and finding the right expertise for a two-day Oncologic Drugs Advisory Committee meeting on four products has been complicated by the Trump Administration’s initial communications freeze and subsequent layoffs in CDER.

More from Agency Leadership